Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)

The purpose of this Notice of Funding Opportunity (NOFO) is to further elucidate the mechanisms of early immune development in utero, during the early post-natal period, and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART). This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity. The opportunity is open to various applicant types, including public and state-controlled institutions of higher education, non-profits, and small businesses. * The award ceiling is $400,000. * The opportunity is for a grant. * The funding activity categories include Health and Income Security and Social Services. * The expected application count is 100. * The application submission deadline is January 7, 2029.